Harvard Apparatus (HART) Regenerative Technology Collaborator Successfully Transplants Regenerated Esophagus Into Rat
4/15/2014 1:34:49 PM
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART. Dr. Macchiarini has previously overseen several successful regenerated trachea transplants in human patients using a bioreactor developed by HART.
Help employers find you! Check out all the jobs and post your resume.
comments powered by